AR053984A1 - Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas - Google Patents
Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativasInfo
- Publication number
- AR053984A1 AR053984A1 ARP050104620A ARP050104620A AR053984A1 AR 053984 A1 AR053984 A1 AR 053984A1 AR P050104620 A ARP050104620 A AR P050104620A AR P050104620 A ARP050104620 A AR P050104620A AR 053984 A1 AR053984 A1 AR 053984A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- treatment
- cinasa
- bcr
- protein
- Prior art date
Links
- 229940118364 Bcr-Abl inhibitor Drugs 0.000 title 1
- 229940122924 Src inhibitor Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 4-methyl-piperazino-methyl Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62493704P | 2004-11-04 | 2004-11-04 | |
| US63212204P | 2004-12-01 | 2004-12-01 | |
| US64972205P | 2005-02-03 | 2005-02-03 | |
| US70362805P | 2005-07-29 | 2005-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053984A1 true AR053984A1 (es) | 2007-05-30 |
Family
ID=36337059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104620A AR053984A1 (es) | 2004-11-04 | 2005-11-03 | Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20060094728A1 (https=) |
| EP (1) | EP1812432A4 (https=) |
| JP (1) | JP2008519049A (https=) |
| KR (1) | KR20070073864A (https=) |
| AR (1) | AR053984A1 (https=) |
| AU (1) | AU2005304863A1 (https=) |
| BR (1) | BRPI0515721A (https=) |
| CA (1) | CA2586649A1 (https=) |
| MX (1) | MX2007005115A (https=) |
| NO (1) | NO20072179L (https=) |
| RU (1) | RU2007120710A (https=) |
| TW (1) | TW200628156A (https=) |
| WO (1) | WO2006052810A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1169038B9 (en) * | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
| WO2006135790A1 (en) * | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant kit protein |
| WO2007047919A2 (en) | 2005-10-20 | 2007-04-26 | University Of South Florida | Treatment of restenosis and stenosis with dasatinib |
| WO2007051862A1 (en) * | 2005-11-07 | 2007-05-10 | Novartis Ag | Combination of organic compounds |
| WO2007109527A1 (en) * | 2006-03-17 | 2007-09-27 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| PL2508523T5 (pl) * | 2007-10-23 | 2020-08-10 | Teva Pharmaceutical Industries Ltd. | Odmiany polimorficzne dasatynibu i sposób ich wytwarzania |
| CN101812060B (zh) * | 2010-02-02 | 2011-08-17 | 南京卡文迪许生物工程技术有限公司 | 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物 |
| CN101891738B (zh) * | 2010-02-08 | 2011-09-28 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
| JP5589097B2 (ja) * | 2010-02-08 | 2014-09-10 | 南京▲か▼文迪許生物工程技術有限公司 | ダサチニブ多結晶体、並びにその調製方法及び薬物組成物 |
| CN102643275B (zh) * | 2011-02-21 | 2016-04-20 | 江苏先声药物研究有限公司 | 一种达莎替尼n-6晶型新的制备方法 |
| CN102838594B (zh) * | 2011-06-24 | 2015-06-24 | 南京圣和药业股份有限公司 | 一种达沙替尼的制备及精制方法 |
| AU2015212341A1 (en) * | 2014-02-03 | 2016-09-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Use of Casein kinase I inhibitors for depleting stem cells |
| WO2024097804A1 (en) | 2022-11-02 | 2024-05-10 | Mdx Management Llc | Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer |
| AU2024239074A1 (en) | 2023-03-17 | 2025-10-02 | Mdx Management Llc | Compositions and methods for ameliorating adverse effects of therapies |
| WO2025188920A1 (en) | 2024-03-06 | 2025-09-12 | Mdx Management Llc | Local application of agents inhibiting tyrosine kinase or shp-1 signaling |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1169038B9 (en) * | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| WO2004071440A2 (en) * | 2003-02-06 | 2004-08-26 | Bristol-Myers Squibb Company | Thiazolyl-based compounds useful as kinase inhibitors |
| US20050009891A1 (en) * | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| ATE481134T1 (de) * | 2004-01-21 | 2010-10-15 | Univ Emory | Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen |
-
2005
- 2005-11-02 TW TW094138488A patent/TW200628156A/zh unknown
- 2005-11-03 US US11/265,843 patent/US20060094728A1/en not_active Abandoned
- 2005-11-03 AR ARP050104620A patent/AR053984A1/es not_active Application Discontinuation
- 2005-11-04 CA CA002586649A patent/CA2586649A1/en not_active Abandoned
- 2005-11-04 MX MX2007005115A patent/MX2007005115A/es not_active Application Discontinuation
- 2005-11-04 RU RU2007120710/04A patent/RU2007120710A/ru not_active Application Discontinuation
- 2005-11-04 JP JP2007540099A patent/JP2008519049A/ja not_active Withdrawn
- 2005-11-04 KR KR1020077010107A patent/KR20070073864A/ko not_active Withdrawn
- 2005-11-04 WO PCT/US2005/040145 patent/WO2006052810A2/en not_active Ceased
- 2005-11-04 AU AU2005304863A patent/AU2005304863A1/en not_active Abandoned
- 2005-11-04 EP EP05816446A patent/EP1812432A4/en not_active Withdrawn
- 2005-11-04 BR BRPI0515721-8A patent/BRPI0515721A/pt not_active IP Right Cessation
-
2007
- 2007-04-27 NO NO20072179A patent/NO20072179L/no not_active Application Discontinuation
-
2008
- 2008-10-21 US US12/254,896 patent/US20090093495A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1812432A4 (en) | 2009-11-25 |
| NO20072179L (no) | 2007-05-31 |
| WO2006052810A2 (en) | 2006-05-18 |
| CA2586649A1 (en) | 2006-05-18 |
| JP2008519049A (ja) | 2008-06-05 |
| US20060094728A1 (en) | 2006-05-04 |
| RU2007120710A (ru) | 2008-12-10 |
| AU2005304863A1 (en) | 2006-05-18 |
| TW200628156A (en) | 2006-08-16 |
| US20090093495A1 (en) | 2009-04-09 |
| WO2006052810A3 (en) | 2007-02-08 |
| BRPI0515721A (pt) | 2008-08-05 |
| EP1812432A2 (en) | 2007-08-01 |
| KR20070073864A (ko) | 2007-07-10 |
| MX2007005115A (es) | 2007-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053984A1 (es) | Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas | |
| ATE321556T1 (de) | Behandlung gastrointestinaler stroma-tumoren | |
| CO6450624A2 (es) | Compuestos vinil indazolilo | |
| GT201100181A (es) | "inhibidores de proteina cinasa" | |
| NO20034713D0 (no) | Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)- benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og et kjemoterapeutiskmiddel | |
| TW200714589A (en) | Phenylacetamides suitable as protein kinase inhibitors | |
| PE20071184A1 (es) | Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo | |
| ATE521354T1 (de) | Kombination aus imatinib und einem histondeacetylase-hemmer zur behandlung von leukämie | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| BR0312873A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante | |
| ATE339197T1 (de) | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten | |
| AR054445A1 (es) | Formulaciones de un inhibidor de src/abl | |
| PE20141337A1 (es) | Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida | |
| TNSN06182A1 (en) | COMBINATION OF (a) N-{5-[4-(4-METHYL-PYPERAZINO-METHYL)-BENZOYLAMIDO] -2-METHYLPHENYL} -4-(3-PYRIDIL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND USE THEREOF | |
| ES2421587T3 (es) | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica | |
| AR111255A1 (es) | Derivados de 4-piperidin-n-(pirimidin-4-il)croman-7-sulfonamidas inhibidores de canales de sodio | |
| DE60319211D1 (de) | Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs | |
| WO2006012958A3 (en) | Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| IS8139A (is) | Notkun týrósínkínasatálma til að meðhöndla sykursýki | |
| BRPI0517083A (pt) | uso de 4-(4-metilpiperazin-1-ilmetil)-n-{4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil}-benzamida para inibir o receptor c-fms de tirosina quinase | |
| CL2008001390A1 (es) | (e)-n-(4nitrobenciliden)-1-(piperidin-4-il)metanamina; proceso de preparacion; y uso dicho compuesto para preparar el compuesto 2-(4-((((1-metil-1h-indol-3-il)metil)amino)metil)piperidin-1-il)-n-((tetrahidro-2h-piran-2-il)oxi)pirimidin-5-carboxamida. | |
| RU2007135284A (ru) | Фармацевтические комбинации ингибиторов киназ bcr-abl и raf | |
| ATE326970T1 (de) | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |